Home
TESARO, Inc.

TESARO, Inc. Market Share Analysis for May 2026

At GSK, we unite science, technology and talent to get ahead of disease together

Health > Biotechnology and Pharmaceuticals

Domaintesarobio.com

Year Founded2010

Employees501 - 1000

Annual Revenue$200M - $500M

TESARO, Inc.

TESARO, Inc. (including company regionals)

tesarobio.com

See more website traffic and engagement information

TESARO, Inc. Revenue up to May 2026 is 200M - 500M

revenue generated by TESARO, Inc. top domains

TESARO, Inc. top domains revenue over 3 years

Revenue for TESARO, Inc. top domains

tesarobio.com200M - 500M

See more with Sales Intelligence

Total visits to TESARO, Inc.'s top domains

Understand TESARO, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in TESARO, Inc.'s top domains

Analyze TESARO, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on TESARO, Inc.'s top domains

See how TESARO, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

TESARO, Inc. top competitors by domain

Top similar sites in May 2026, ranked by their affinity

progenics.comCompany NameProgenics Pharmaceuticals, Inc.Employees51 - 200HQUnited States, New York, New YorkAnnual revenue$25M - $50MTotal visits--Health > Biotechnology and Pharmaceuticals

Top technologies used by TESARO, Inc.

These are the website technologies, by industry, used by TESARO, Inc. top domains

Conversion & Analytics (5)

Google Analytics

Marketing (4)

Google Marketing Platform

Social (4)

Instagram

Widget (3)

reCAPTCHA

More Technologies

10

See all

News & Signals from TESARO, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsALTEOGEN Inc. partnered with Tesaro Inc on Jan 1st '26.In January 2026, Alteogen entered an exclusive licence agreement with Tesaro, a GSK subsidiary, for the use of ALT-B4 in the development and commercialisation of a subcutaneous formulation of dostarlimab.

NewsAnaptysBio, Inc. filed suit against Tesaro Inc on Jul 1st '14.AnaptysBio promptly filed a countersuit claiming that Tesaro, under pressure from GSK, had unlawfully modified the terms of the 2014 agreement.

NewsTesaro Inc is developing Jemperli on Apr 24th '26.Currently, under the Collaboration Agreement, Tesaro is developing Jemperli (dostarlimab) as a monotherapy, and in combination with additional therapies, for various solid tumor indications.